Sector: MedicalCYCLACEL PHARMACEUTI (NASDAQ: CYCC)

CYCC Ranking Chart

Ranking History

Please login to view our current ranking data

Click here to login

Headlines

NYSSA Presents 13th Annual Biotech and Specialty Pharmaceuticals Conference
Nov 20, 2009 03:02 PM | CYCC, ECTE, EMIS, INO, PVCT
Cyclacel Pharmaceuticals to Present Sapacitabine Phase 2 AML & MDS Data at the Upcoming American Society of Hematology Meeting
Nov 17, 2009 07:02 AM | CYCC
Cyclacel Pharmaceuticals Announces Third Quarter 2009 Financial Results
Nov 03, 2009 04:03 PM | CYCC
Cyclacel Pharmaceuticals Reports Survival Data From Phase 2 Sapacitabine Study in Elderly Patients With Acute Myeloid Leukemia
Oct 28, 2009 04:13 PM | CYCC
Cyclacel Pharmaceuticals Third Quarter 2009 Financial Results Conference Call On Tuesday November 3 & Upcoming Conference Presentations
Oct 28, 2009 07:05 AM | CYCC
Cyclacel Pharmaceuticals to Present at BIO Investor Forum
Oct 21, 2009 07:03 AM | CYCC
Cyclacel to Present At Annual Rodman & Renshaw Healthcare Conference
Sep 03, 2009 04:02 PM | CYCC
Cyclacel Pharmaceuticals Announces Receipt of NASDAQ Notice
Aug 28, 2009 04:02 PM | CYCC, NDAQ
Biotech Industry Overview
Jun 01, 2009 10:43 AM | ALKS, AMAG, CRA, CTIC, CYCC, DCGN
Biotech Industry - Industry Outlook
Apr 16, 2009 04:59 PM | ALKS, AMAG, CELG, CEPH, CRA, CTIC
More..

Analyst Ratings

CYCC Analyst Chart

Sentiment Survey

Avg. Short Term

Avg. Long Term

Avg. Grade

Share Performance

Period	CYCC	Compare to S&P
YTD	95.24 %	61.27 %
4 Weeks	-14.58 %	-15.04 %
12 Weeks	-16.50 %	-21.64 %
More...

Financial Ratios

CYCC Financial Ratios Chart

Earnings Performance

EPS Growth in Last Quarter: 45.83 %

EPS Growth in Last Year: 56.67 %

Sales Growth in Last Quarter: -13.53 %

Sales Growth in Last Quarter: -14.50 %

Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia